https://www.liftbiosciences.com/
Innately Curing CancerLIfT BioSciences is a socially-minded Biotech start-up developing The World's First Cell Bank of Cancer Killing Granulocytes (a type of white blood cell). The Cell Bank will enable us to provide a range of potentially life-saving immuno-oncology cell therapies for different solid tumour types. Our innate immunity platform is known as Leukocyte Infusion Therapy (LIfT). LIfT BioSciences Ltd was set-up with Prof Zhen Cui of Wake Forest University, a leading pioneer in LIFT, following his discovery of a cancer resistant (SR/CR) mouse that proved to have transferable innate immunity.The first targeted indication is pancreatic cancer (pancreatic ductal adenocarcinoma – PDAC), one of the types of cancer with the highest unmet medical need. CRUK report that just 3% of Patients Diagnosed with PDAC survive 5 years. PDAC is classified as an orphan disease by European Medicines Agency (EMA) which will facilitate our market access. The EMA has classified LIfT as an Advanced Therapeutic Medicinal Product (ATMP), which sets us up for accelerated approval (early access scheme) and enhanced proprietary protection (market and data exclusivity), subject to trial results.We are currently completing pre-clinical work before running our first in-human clinical trial. The aim is to demonstrate by 2021 that LIfT is curative for Pancreatic Cancer.
